Dr Rodón talks to ecancertv at ESMO 2016 about the innovative uses of a new kinase inhibitor for angiogenesis and fibroblast growth factor receptors.
He also discusses how some tumours with genetic alterations could benefit from the use of this new class of drug.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.